CAMBRIDGE, Mass.– Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced a revised supply agreement with the Government of Canada for up to 105 million doses of Moderna’s COVID-19 vaccine and its booster vaccine candidate, if authorized, for delivery through 2024.
The agreement provides for 20 million doses each year in 2022 and 2023, with an option for an additional 15 million doses each year. For 2024, the agreement provides an option for up to 35 million doses.
“We thank the Government of Canada for their support in this supply agreement for our mRNA COVID-19 vaccine and booster candidate, if approved,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “This agreement reflects the efforts of the Canadian government to address the ongoing pandemic and builds on our existing collaboration to protect Canadian citizens.”
